Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/18005960/ below:

Aspirin dose and duration of use and risk of colorectal cancer in men

Affiliations

• ¹ Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, USA.

• PMID: 18005960
• PMCID: PMC2719297
• DOI: 10.1053/j.gastro.2007.09.035

Item in Clipboard

Andrew T Chan et al. Gastroenterology. 2008 Jan.

• ¹ Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, USA.

• PMID: 18005960
• PMCID: PMC2719297
• DOI: 10.1053/j.gastro.2007.09.035

Item in Clipboard

Background & aims: Long-term data on the risk of colorectal cancer according to dose, duration, and consistency of aspirin therapy are limited.

Methods: We conducted a prospective study of 47,363 male health professionals who were ages 40-75 years at enrollment in 1986. Biennially, we collected data on aspirin use, other risk factors, and diagnoses of colorectal cancer. We confirmed all reports of colorectal cancer through 2004 by review of medical records.

Results: During 18 years of follow-up, we documented 975 cases of colorectal cancer over 761,757 person-years. After adjustment for risk factors, men who regularly used aspirin (>/=2 times per week) had a multivariate relative risk (RR) for colorectal cancer of 0.79 (95% confidence interval, [CI], 0.69-0.90) compared with nonregular users. However, significant risk reduction required at least 6-10 years of use (P for trend = .008) and was no longer evident within 4 years of discontinuing use (multivariate RR, 1.00; CI, 0.72-1.39). The benefit appeared related to increasing cumulative average dose: compared with men who denied any aspirin use, the multivariate RRs for cancer were 0.94 (CI, 0.75-1.18) for men who used 0.5-1.5 standard aspirin tablets per week, 0.80 (CI, 0.63-1.01) for 2-5 aspirin tablets per week, 0.72 (CI, 0.56-0.92) for 6-14 aspirin tablets per week, and 0.30 (CI, 0.11-0.81) for >14 aspirin tablets per week (P for trend = .004).

Conclusions: Regular, long-term aspirin use reduces risk of colorectal cancer among men. However, the benefit of aspirin necessitates at least 6 years of consistent use, with maximal risk reduction at doses greater than 14 tablets per week. The potential hazards associated with long-term use of such doses should be carefully considered.

PubMed Disclaimer

All authors have no conflict of interests to disclose.

• Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer.

  Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Chan AT, et al. JAMA. 2005 Aug 24;294(8):914-23. doi: 10.1001/jama.294.8.914. JAMA. 2005. PMID: 16118381 Free PMC article.

• A prospective study of aspirin use and the risk for colorectal adenoma.

  Chan AT, Giovannucci EL, Schernhammer ES, Colditz GA, Hunter DJ, Willett WC, Fuchs CS. Chan AT, et al. Ann Intern Med. 2004 Feb 3;140(3):157-66. doi: 10.7326/0003-4819-140-3-200402030-00006. Ann Intern Med. 2004. PMID: 14757613

• A prospective study of aspirin use and the risk of pancreatic cancer in women.

  Schernhammer ES, Kang JH, Chan AT, Michaud DS, Skinner HG, Giovannucci E, Colditz GA, Fuchs CS. Schernhammer ES, et al. J Natl Cancer Inst. 2004 Jan 7;96(1):22-8. doi: 10.1093/jnci/djh001. J Natl Cancer Inst. 2004. PMID: 14709735

• Effect of aspirin and NSAIDs on risk and survival from colorectal cancer.

  Din FV, Theodoratou E, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R, Stark L, Porteous ME, Campbell H, Dunlop MG. Din FV, et al. Gut. 2010 Dec;59(12):1670-9. doi: 10.1136/gut.2009.203000. Epub 2010 Sep 15. Gut. 2010. PMID: 20844293 Review.

• The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.

  Dubé C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D; U.S. Preventive Services Task Force. Dubé C, et al. Ann Intern Med. 2007 Mar 6;146(5):365-75. doi: 10.7326/0003-4819-146-5-200703060-00009. Ann Intern Med. 2007. PMID: 17339622 Review.

• Fruit and vegetable consumption is associated with lower prevalence of asymptomatic diverticulosis: a cross-sectional colonoscopy-based study.

  Maxner B, McGoldrick J, Bellavance D, Liu PH, Xavier RJ, Yarze JC, Ricciardi R, Staller K, Chung DC, Khalili H. Maxner B, et al. BMC Gastroenterol. 2020 Jul 11;20(1):221. doi: 10.1186/s12876-020-01374-0. BMC Gastroenterol. 2020. PMID: 32652931 Free PMC article.

• The role of aspirin in the prevention of ovarian, endometrial and cervical cancers.

  Joharatnam-Hogan N, Cafferty FH, Macnair A, Ring A, Langley RE. Joharatnam-Hogan N, et al. Womens Health (Lond). 2020 Jan-Dec;16:1745506520961710. doi: 10.1177/1745506520961710. Womens Health (Lond). 2020. PMID: 33019903 Free PMC article. Review.

• Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward.

  Menter DG, Schilsky RL, DuBois RN. Menter DG, et al. Clin Cancer Res. 2010 Mar 1;16(5):1384-90. doi: 10.1158/1078-0432.CCR-09-0788. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179228 Free PMC article. Review.

• Regular aspirin use and risk of multiple myeloma: a prospective analysis in the health professionals follow-up study and nurses' health study.

  Birmann BM, Giovannucci EL, Rosner BA, Colditz GA. Birmann BM, et al. Cancer Prev Res (Phila). 2014 Jan;7(1):33-41. doi: 10.1158/1940-6207.CAPR-13-0224. Epub 2013 Nov 26. Cancer Prev Res (Phila). 2014. PMID: 24282256 Free PMC article.

• Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort.

  Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A, Cross AJ. Ruder EH, et al. Am J Gastroenterol. 2011 Jul;106(7):1340-50. doi: 10.1038/ajg.2011.38. Epub 2011 Mar 15. Am J Gastroenterol. 2011. PMID: 21407185 Free PMC article.

1. 1. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891–9. - PubMed
2. 1. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883–90. - PubMed
3. 1. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, Couturier D, Coste T, Little J, Chaussade S. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology. 2003;125:328–36. - PubMed
4. 1. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. Jama. 2005;294:47–55. - PubMed
5. 1. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst. 1993;85:1220–4. - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3